Gossamer Bio, Inc.
NASDAQ:GOSSBiotechnology
+$0.01 today
- Market cap
- $69.91M
- Beta
- 2.04
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$0.77
Volume 0.24M
Average 19.76M
GOSS Short-term Investments
Marketable securities and deposits the company expects to convert to cash within a year.
Gossamer Bio, Inc.NASDAQ: GOSS
Short-term Investments · Q1 FY2026 · quarter ended Mar 2026
Short-term investments falls 74.6% from a year ago
Short-term investments stood at $58.19M at the end of Q1 FY2026, down 74.6% from a year earlier and down 41.3% from the prior quarter. Over 3 fiscal years it compounded at -11.6% a year.
Context
- Short-term investments amounted to 45.1% of total assets at the end of Q1 FY2026, down 36.4 pp from a year earlier.
- Short-term investments increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether short-term investments keeps falling in the next quarterly balance sheet after a -74.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Investments history
USD · from the balance sheet
- Latest · FY2025
- 99.2M USD
- Year-over-year change
- -60.1%
- 4-year CAGR
- -8.5%
| Period | Period end | Short-term Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 99.2M | -60.1% |
| FY2024 | 2024-12-31 | 248.44M | -6.0% |
| FY2023 | 2023-12-31 | 264.32M | +83.9% |
| FY2022 | 2022-12-31 | 143.71M | +1.3% |
| FY2021 | 2021-12-31 | 141.82M | — |
Short-term Investments vs competitors
How GOSS compares with its peers on the latest reported figures
- GOSS's Mar 2026 short-term investments of $58.19M is the 8th highest of the 9 companies compared; the peer median is $133.92M.
- Its year-over-year change of -74.6% is the lowest of 7, against a peer median of +50.9%.
- Short-term investments amounts to 45.1% of total assets for GOSS, versus a peer median of 44.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $452.8M | +32.4% | +36.3% | 85.3% | |
| Mar 2026 | $318.4M | +69.4% | +28.5% | 62.1% | |
| Mar 2026 | $196.61M | +401.4% | +21.4% | 77.7% | |
| Mar 2026 | $135.26M | -1.8% | -9.9% | 39.6% | |
| Mar 2026 | $132.57M | +0.5% | -12.4% | 49.3% | |
| Mar 2026 | $122.27M | +289.8% | +50.2% | 24.2% | |
| Dec 2025 | $70.87M | — | — | 21.1% | |
| Mar 2026 | $58.19M | -74.6% | -11.6% | 45.1% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding GOSS) | $133.92M | +50.9% | +25.0% | 44.4% | |
Competitors are the stored peer set for GOSS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 183.4M | 111.97M | 32.11M | 46.07M | 37.73M |
| Short-term Investments | 141.82M | 143.71M | 264.32M | 248.44M | 99.2M |
| Net Receivables | 0 | 0 | 0 | 5.34M | 12.53M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 64K | 0 | 10.09M | 10.03M | 18.19M |
| Total Current Assets | 331.78M | 261.88M | 306.52M | 309.89M | 167.64M |
| Property, Plant & Equipment (Net) | 10.8M | 9.89M | 4.78M | 5.12M | 4.2M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1.08M | 680K | 618K | 283K | 408K |
| Total Non-current Assets | 11.88M | 10.57M | 5.4M | 5.4M | 4.61M |
| Total Assets | 343.66M | 272.45M | 311.92M | 315.29M | 172.25M |
| Account Payables | 3.24M | 1.46M | 5.53M | 2.32M | 5.96M |
| Short-term Debt | 0 | 11.61M | 11.61M | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 17.05M | 19.99M |
| Other Current Liabilities | 11.92M | 13.53M | 10.29M | 12M | 11.21M |
| Total Current Liabilities | 39.86M | 49.23M | 51.6M | 45.01M | 63.44M |
| Long-term Debt | 179.12M | 207.7M | 197.41M | 197.52M | 198.51M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 38.87M | 29.61M |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 182.34M | 211.14M | 197.55M | 240.79M | 231.57M |
| Total Liabilities | 222.19M | 260.37M | 249.15M | 285.8M | 295.01M |
| Common Stock | 8K | 10K | 23K | 23K | 24K |
| Retained Earnings | (811.53M) | (1.03B) | (1.21B) | (1.27B) | (1.44B) |
| Accumulated OCI | 45K | (574K) | (350K) | 1.19M | (5.15M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 121.46M | 12.08M | 62.77M | 29.49M | (122.76M) |
| Total Debt | 185.24M | 225.74M | 212.46M | 202.88M | 202.91M |
| Net Debt | 1.83M | 113.77M | 180.36M | 156.81M | 165.17M |
Gossamer Bio, Inc.
NASDAQ:GOSS
Intrinsic Alpha fair value
Locked
Current Price
$11.43
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.